Loading patent…
AssigneeBoryung Corporation
InventorsBong-Seog KIM, Hyo Soon JUNG, Kyoung Ryun PARK, Seungho WANG, Seung Hee JUNG, Yoon Sik KIM, Joo Han LEE, Byeongwook JEON, Jongyeon KIM, Tae Min KIM, Seok Jin KIM, Dok Hyun YOON, Yoon Kyung JEON, Ahmad H. MATTOUR, Jorge M. CHAVES
Estimating the term…
A composition for preventing or treating peripheral T-cell lymphoma includes a compound represented by formula 1 or pharmaceutically acceptable salts thereof. Specifically, a pharmaceutical composition based on the composition is capable of effectively ameliorating peripheral T-cell lymphoma by decreasing regulatory T cells and increasing CD8+ T cells. The pharmaceutical composition may exhibit anticancer activity against peripheral T-cell lymphoma by decreasing regulatory T cells which suppress immune responses and increasing CD8+ T cells which exhibit anticancer activity. In addition, the pharmaceutical composition is used for the treatment of peripheral T-cell lymphoma due to excellent safety and tolerability.
A pharmaceutical composition for preventing or treating peripheral T-cell lymphoma (PTCL), comprising a compound represented by formula 1 below or pharmaceutically acceptable salts thereof in an amount of 25 mg or more and less than 325 mg as a compound represented by formula 1:
Dependencies are inferred from the claim text.